JP2023529095A5 - - Google Patents
Info
- Publication number
- JP2023529095A5 JP2023529095A5 JP2022573504A JP2022573504A JP2023529095A5 JP 2023529095 A5 JP2023529095 A5 JP 2023529095A5 JP 2022573504 A JP2022573504 A JP 2022573504A JP 2022573504 A JP2022573504 A JP 2022573504A JP 2023529095 A5 JP2023529095 A5 JP 2023529095A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20178574.8 | 2020-06-05 | ||
| EP20178574 | 2020-06-05 | ||
| PCT/EP2021/064986 WO2021245223A1 (en) | 2020-06-05 | 2021-06-04 | High dose and low volume botulinum toxin treatment of facial wrinkles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529095A JP2023529095A (ja) | 2023-07-07 |
| JPWO2021245223A5 JPWO2021245223A5 (https=) | 2024-06-03 |
| JP2023529095A5 true JP2023529095A5 (https=) | 2024-06-03 |
Family
ID=71016459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573504A Pending JP2023529095A (ja) | 2020-06-05 | 2021-06-04 | 高用量低体積のボツリヌス毒素による顔のシワの治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12599550B2 (https=) |
| EP (2) | EP4161562B1 (https=) |
| JP (1) | JP2023529095A (https=) |
| KR (1) | KR20230020961A (https=) |
| CN (1) | CN115666629A (https=) |
| AU (1) | AU2021286196A1 (https=) |
| BR (1) | BR112022023413A2 (https=) |
| CA (1) | CA3177835A1 (https=) |
| ES (1) | ES3013130T3 (https=) |
| IL (1) | IL298399A (https=) |
| MX (1) | MX2022014564A (https=) |
| TW (1) | TW202214211A (https=) |
| WO (1) | WO2021245223A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298399A (en) | 2020-06-05 | 2023-01-01 | Merz Pharma Gmbh & Co Kgaa | Treatment of facial wrinkles with the botulinum toxin in high dose and low volume |
| KR20240169045A (ko) * | 2022-04-01 | 2024-12-02 | 충칭 클라루비스 파마슈티컬 컴퍼니 리미티드 | 보툴리눔 독소 단백질 조성물, 이의 제조 방법 및 용도 |
| EP4626556A1 (en) * | 2022-11-28 | 2025-10-08 | Merz Pharma GmbH & Co. KGaA | High concentration botulinum toxin treatment for neck rejuvenation |
| WO2025231403A1 (en) * | 2024-05-03 | 2025-11-06 | Revivity Pharma Corporation | Methods of administering and manufacturing toxic compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| BRPI0513850A (pt) | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| EP2072039A1 (en) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| PL2271670T3 (pl) | 2008-03-14 | 2015-05-29 | Allergan Inc | Testy aktywności serotypu A toksyny botulinowej oparte na immunologii |
| HUE037509T2 (hu) * | 2011-09-29 | 2018-09-28 | Cellsnap Llc | Készítmények és eljárások toxigenicitás meghatározására |
| PL3014267T3 (pl) * | 2013-06-28 | 2019-05-31 | Merz Pharma Gmbh & Co Kgaa | Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| SG11202005239YA (en) * | 2017-12-04 | 2020-07-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
| IL298399A (en) | 2020-06-05 | 2023-01-01 | Merz Pharma Gmbh & Co Kgaa | Treatment of facial wrinkles with the botulinum toxin in high dose and low volume |
-
2021
- 2021-06-04 IL IL298399A patent/IL298399A/en unknown
- 2021-06-04 US US18/007,712 patent/US12599550B2/en active Active
- 2021-06-04 EP EP21728601.2A patent/EP4161562B1/en active Active
- 2021-06-04 KR KR1020227040449A patent/KR20230020961A/ko active Pending
- 2021-06-04 ES ES21728601T patent/ES3013130T3/es active Active
- 2021-06-04 TW TW110120421A patent/TW202214211A/zh unknown
- 2021-06-04 JP JP2022573504A patent/JP2023529095A/ja active Pending
- 2021-06-04 AU AU2021286196A patent/AU2021286196A1/en active Pending
- 2021-06-04 CA CA3177835A patent/CA3177835A1/en active Pending
- 2021-06-04 CN CN202180037805.1A patent/CN115666629A/zh active Pending
- 2021-06-04 BR BR112022023413A patent/BR112022023413A2/pt unknown
- 2021-06-04 EP EP24206746.0A patent/EP4467202A3/en active Pending
- 2021-06-04 MX MX2022014564A patent/MX2022014564A/es unknown
- 2021-06-04 WO PCT/EP2021/064986 patent/WO2021245223A1/en not_active Ceased